Revance and Teoxane Announce RHA(R) Dynamic Volume is Available Now

FDA-approved for cheek augmentation and/or age-related midface contour deficiencies, in adults aged 22 years or older, RHA(R) Dynamic Volume delivers natural-looking results by addressing volume loss ...
Yahoo Finance

Revance and Teoxane Announce the FDA Approval of RHA® Dynamic Volume for Midface Contour Deficiencies

NASHVILLE, Tenn., Jan. 13, 2026 /PRNewswire/ -- Revance and Teoxane announce the FDA approval of RHA ® Dynamic Volume from the Teoxane RHA ® Collection for cheek augmentation and/or the correction of ...
Business Wire

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. – Q4 DAXXIFY volume up 22% ...
Business Wire

Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...

Revance and Teoxane Announce RHA® Dynamic Volume is Available Now

Revance and Teoxane announce today that RHA®Dynamic Volume, formerly RHA® 4 Mepi, is now available. RHA® Dynamic Volume is a product designed with unique rheology to adapt to facial movements and ...
Nasdaq

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue ...